|
Age group years)
|
|
30–39
|
25.2
|
74.8
|
1
| | |
40.3
|
59.7
|
1
| | |
|
40–49
|
20.9
|
79.1
|
0.78
|
0.43–1.41
|
0.415
|
43.7
|
56.3
|
1.15
|
0.74–1.78
|
0.527
|
|
50–59
|
26.8
|
73.2
|
1.09
|
0.63–1.88
|
0.767
|
57.9
|
42.1
|
2.04
|
1.33–3.12
|
0.001
|
|
60–69
|
38.6
|
61.4
|
1.86
|
1.14–3.05
|
0.013
|
55.9
|
44.1
|
1.89
|
1.25–2.84
|
0.003
|
|
Formal education period
|
|
High school graduate and
|
30.4
|
69.6
|
1
| | |
47.9
|
52.1
|
1
| | |
|
College and higher
|
31.1
|
68.9
|
0.97
|
0.69–1.35
|
0.844
|
53.9
|
46.1
|
0.79
|
0.59–1.06
|
0.109
|
|
Self-rated understanding of terminology
|
|
High
|
37.3
|
62.7
|
1
| | |
62.8
|
37.2
|
1
| | |
|
Middle
|
30.7
|
69.3
|
0.74
|
0.51–1.08
|
0.122
|
51.5
|
48.5
|
0.63
|
0.43–0.92
|
0.018
|
|
Low
|
21.1
|
78.9
|
0.45
|
0.29–0.69
|
<0.001
|
41.6
|
58.4
|
0.42
|
0.29–0.62
|
<0.001
|
|
Awareness of benefits
|
|
Helpful for disease diagnosis
|
91.1
|
79.0
|
2.73
|
1.60–4.66
|
<0.001
|
90.2
|
77.0
|
2.76
|
1.80–4.23
|
<0.001
|
|
Helpful for disease treatment
|
93.2
|
78.3
|
3.77
|
2.10–6.78
|
<0.001
|
89.1
|
76.5
|
2.51
|
1.66–3.79
|
<0.001
|
|
Helpful for disease prevention
|
90.2
|
75.7
|
2.96
|
1.78–4.92
|
<0.001
|
89.1
|
77.0
|
2.44
|
1.61–3.70
|
<0.001
|
|
Concerns
|
|
Financial infusion
|
79.7
|
77.7
|
1.13
|
0.75–1.69
|
0.572
|
78.7
|
74.4
|
1.27
|
0.90–1.80
|
0.180
|
|
Privacy concerns
|
57.7
|
61.7
|
0.85
|
0.61–1.19
|
0.339
|
56.3
|
52.8
|
1.15
|
0.86–1.55
|
0.355
|
|
Discriminations
|
40.4
|
45.0
|
0.83
|
0.59–1.16
|
0.275
|
38.5
|
37.2
|
1.06
|
0.78–1.44
|
0.711
|
|
Unexpected negative effects
|
34.0
|
42.8
|
0.68
|
0.49–0.97
|
0.034
|
30.5
|
32.6
|
0.91
|
0.66–1.25
|
0.564
|
|
Cloned human beings
|
33.5
|
37.0
|
0.86
|
0.61–1.22
|
0.387
|
29.0
|
32.0
|
0.87
|
0.63–1.20
|
0.391
|
|
Belief
|
|
Company or government bodies use genome information
|
44.5
|
45.6
|
0.96
|
0.69–1.34
|
0.796
|
39.9
|
38.8
|
1.05
|
0.78–1.42
|
0.758
|
